Table 2.
Single-Agent mTOR Inhibitor Studies in Endometrial Cancer
| Agent | Patients | Prior Chemotherapy Regimens | Molecular Selection of Patients | Objective Response Rate | Other Activity |
|---|---|---|---|---|---|
| Temsirolimus [112] | 29 | None | No | 24% | SD ≥ 8 weeks: 69% |
| 25 | 1–2 | No | 4% | SD ≥ 8 weeks: 46% | |
| Everolimus [113] | 28 | 1–2 | No | 0% | SD: 43% |
| Everolimus [114] | 44 | 1–2 | No | 9% | SD: 27% |
| Ridaforolimus IV [115] | 45 | 1–2 | No | 11% | CBR: 29% |
| Ridaforolimus PO [116] | 30 | Adjuvant only | No | 9% | SD: 52.9% |
| Ridaforolimus PO [117] | 64 | 1–2 | No | 0% | SD: 35% |
IV intravenous, PO oral, SD stable disease, CBR clinical benefit rate